References
- D'Incalci M., Garattini S. Podophyllotoxin derivatives VP-16 and VM-26. Cancer Chemotherapy and Biological Modifiers, H. M. Pinedo, D. L. Longo, B. A. Chabner. Elsevier, Amsterdam 1987; 67–70, Annual 9
- Van Maanen J. M.S., Retel J., de Vries J., Pinedo H. M. Mechanism of action of antitumor drug etoposide: a review. Journal of the National Cancer Institute 1988; 80: 1526–1533
- Sinha B. K. Free radicals in anticancer drug pharmacology. Chem-Biol. Interaction 1989; 69: 293–317
- Haim N., Nemec J., Roman J., Sinha B. K. In vitro metabolism of etoposide (VP-16,213) by liver microsomes and irreversible binding of reactive intermediates to microsomal proteins. Biochemical Pharmacology 1987; 36: 527–536
- Sinha B. K., Eliot H. M., Kalayanaraman B. Iron-dependent hydroxyl radical formation and DNA damage from a novel metabolite of the clinically active antitumor drug. VP-16. FEBS Letters 1988; 227: 240–244
- Van Maanen J. M.S., Laflcur M. V.M., Mans D. R.A., van Den Ackker E., DeRuiter C., Koostra P. R., Pappie D., deVaries J., Retel J., Pinedo H. M. Effects of ortho-quinone and catechol of the antitumor drug VP-16–213 on the biological activity of single-stranded and double-stranded X174 DNA. Biochemical Pharmacology 1988; 37: 3579–3589
- Wick M. M., Byers L., Frei E., III. L-dopa: selective toxicity for melanoma cells in vitro. Science 1977; 197: 468–469
- Wick M. M. Dopamine: a novel antitumor agent active against B-16 melanoma in vivo. Journal of Investigation in Dermatology 1978; 71: 163–164
- Wick M. M. Therapeutic effects of dopamine infusion on human malignant melanoma. Cancer Treatment Report 1982; 68: 1657–1659
- Kable E. P., Favier D., Parsons P. G. Sensitivity of human melanoma cells to L-dopa and DL-buthionine (S,R) sulfoximine. Cancer Research 1989; 49: 2327–2331
- Kern D. H., Shoemaker R. H., Hildebrand-Zanki S. U., Driscoll J. S. Structure-activity relationships defining the cytotoxicity of catechol analogues against human malignant melanoma. Cancer Research 1988; 48: 5178–5182
- Pomerantz S. H. The tyrosinase hydroxylase activity of mammalian tyrosinase. Journal of Biological Chemistry 1968; 241: 161–168
- Katki A. G., Kalyanaraman B., Sinha B. K. Interactions of antitumor drug etoposide with reduced thiols in vitro and in vivo. Chem.-Biol. Interaction 1987; 62: 237–247
- Loike J. D., Horwitz S. B. Effects of VP16-213 on the intracellular degradation of DNA in HeLa cells. Biochemistry 1976; 15: 5443–5448
- Glisson B., Gupta R., Smallwood-Kentro S., Ross W. Characterization of aquired epipodophyllotoxin resistance in Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res. 1987; 46: 1934–1938
- Long B. H., Musial S. T., Brattain M. G. Comparison of cytotoxicity and DNA berakage activity of congeners of podophylotoxin including VP-16-213 and VM-26: a quantitative structure-activity relationship. Biochemistry 1984; 23: 1183–1188
- Sinha B. K., Haim N., Dusre L., Kerrigan D., Pommier Y. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor eels: implications for the mechanism of action. Cancer Research 1988; 48: 5096–5100
- Sinha B. K. Role of free radicals in etoposide (VP-16,213) action. Oxygen radicals in biology and medicine, M. G. Simic, K. A. Taylor, J. F. Ward, C. von Sonntag. Plenum Publishing Co. 1989; 765–768
- Kalyanaraman B., Nemec J., Sinha B. K. Characterization of free radicals prouced during oxidation of etoposide (VP-16) and its catechol and quinone derivatives. An ESR study. Biochemistry 1989; 28: 4839–4846